Edward Davis, Leonardo Alexander, Bernard C Fernando, Gabriel Tandexci, Tao-Wei Chang, Jung-Cheng Hsu, Yen-Wen Wu, Denio A Ridjab, Linawati Hananta
{"title":"Impact of Trimetazidine on Echocardiographic Indices and Clinical Outcomes in Ischemic Cardiomyopathy: An Updated Meta-Analysis of Clinical Trials.","authors":"Edward Davis, Leonardo Alexander, Bernard C Fernando, Gabriel Tandexci, Tao-Wei Chang, Jung-Cheng Hsu, Yen-Wen Wu, Denio A Ridjab, Linawati Hananta","doi":"10.1097/FJC.0000000000001888","DOIUrl":"10.1097/FJC.0000000000001888","url":null,"abstract":"<p><p>Ischemic cardiomyopathy (ICM) is a major cause of chronic heart failure with impaired left ventricular (LV) function. This meta-analysis aimed to evaluate trimetazidine's effect in patients with ICM compared to standard therapy alone. A systematic search was conducted across PubMed, ProQuest, SAGE, EBSCO Host, Wiley, Science Direct, Springer link, Clinicaltrials.gov , EMBASE, WHO ICTRP databases until November 2024. Clinical trials assessing trimetazidine versus standard therapy in ICM were included. Data were analyzed using a random-effects model to calculate mean differences (MD) and relative risk (RR), with heterogeneity evaluated using the I 2 statistic. Twelve studies met the inclusion criteria. Trimetazidine significantly improved left ventricular ejection fraction (MD 6.35, 95% CI: 4.63- 8.07, p < 0.05, I2 = 69%), reduced LV end-systolic diameter (MD -4.51, 95% CI: -6.21- -2.81, p < 0.05, I2 = 56%), LV end-diastolic diameter (MD -3.13, 95% CI: -6.07- -0.18, p < 0.05, I2 = 86%), and LV end-systolic volume (MD -14.20, 95% CI: -21.19- -7.21, p < 0.05, I2 = 72%). There was no significant difference in left ventricular end-diastolic volume. Exercise capacity improved with a mean increase of 83.64 meters in the 6-minute walking test (MD 83.64, 95% CI: 22.88- 144.41, p < 0.05, I2 = 96%). NYHA class also improved (MD -0.80, 95% CI: -1.48- -0.12, p <0.05, I2 = 97%). Trimetazidine significantly reduced nitrate consumption (MD -2.76, 95% CI -3.84 to -1.68; I 2 = 95%), while its effect on anginal episodes was not significant (MD -1.52, 95% CI -4.49 to 1.46; I 2 = 99%) but became significant after excluding a study with an imputed standard deviation. Trimetazidine as an adjunct to standard therapy may improve cardiac function and exercise capacity in ischemic cardiomyopathy patients. The findings of this meta-analysis must be interpreted with caution due to high heterogeneity in some outcomes. Further large-scale trials are warranted to assess long-term outcomes such as mortality and hospitalization.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chenchen Wei, Yan Zhou, Xuefeng Xu, Zhixiao Shao, Ping Li, Qian Zhang, Zhongshan Gou, Xinxin Yan
{"title":"Association Between Serum FGF21 Levels and Isolated Aortic Valve Calcification.","authors":"Chenchen Wei, Yan Zhou, Xuefeng Xu, Zhixiao Shao, Ping Li, Qian Zhang, Zhongshan Gou, Xinxin Yan","doi":"10.1097/FJC.0000000000001897","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001897","url":null,"abstract":"<p><p>Aortic valve calcification (AVC) is a progressive pathological process, eventually leading to valve dysfunction. We aimed to examine the association between fibroblast growth factor 21 (FGF21) and AVC. Forty-three patients with confirmed isolated AVC (without valve incompetence) and seventeen control individuals were included. Patients with AVC were older (P < 0.001) and exhibited higher serum levels of IL-2, IL-4, IL-6, and IFN-γ (P < 0.05) than the control group did. Importantly, the serum FGF21 levels of the patients with AVC were higher than those of the control individuals (P < 0.001). Linear regression analysis showed that the presence of AVC and the serum IL-4 levels significantly affected FGF21 levels. Multivariate logistic regression revealed that FGF21 levels and age were strong independent factors that influenced AVC. The area under the ROC curve (AUC) of the combined diagnosis of AVC with FGF21 levels and age was 0.941 (95% CI 0.855-0.981; P < 0 .001). Therefore, elevated serum FGF21 levels were robustly associated with the presence of AVC. FGF21 levels showed a positive correlation with IL-4 levels, suggesting possible interactions among FGF21, inflammation, and AVC.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149357492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Giuseppe Biondi-Zoccai, Salvatore Giordano, Nicola Corcione, George W Booz
{"title":"Micropeptides: challenges and opportunities in cardiovascular pharmacology.","authors":"Giuseppe Biondi-Zoccai, Salvatore Giordano, Nicola Corcione, George W Booz","doi":"10.1097/FJC.0000000000001898","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001898","url":null,"abstract":"<p><p>Micropeptides are small proteins that generally comprise fewer than 100 amino acids and are translated from short or noncanonical open reading frames. They were long overlooked, but their role is being actively explored as biologically active regulators with potential pharmacological relevance. Advances in ribosome profiling, proteogenomics, peptidomics, and computational modelling have enabled the identification and characterization of a substantially larger repertoire of micropeptides. Yet, it is important to focus on rigorous validation of endogenous translation, molecular targets, concentration-dependent activity, and peptide-specific effects. In particular, cardiovascular micropeptides can regulate myocardial calcium handling and contractility, exemplified by DWORF, which activates sarcoplasmic reticulum Ca2+-ATPase 2a and has shown therapeutic potential in multiple preclinical models of cardiomyopathy and heart failure. Other candidates, including mitoregulin, mitolamban, BRAWNIN, IAMP, SPAAR, and MFRLP, have been linked to distinct aspects of mitochondrial bioenergetics, inflammatory signalling, ischemia-reperfusion injury, angiogenesis, vascular smooth-muscle phenotypic switching, and arterial remodeling. Collectively, these findings suggest that micropeptides may provide novel therapeutic targets or pharmacological tools across several cardiovascular conditions, including heart failure, ischemia-reperfusion injury, and vascular remodeling. However, clinical translation will require advances in tissue-specific delivery, control of expression and stoichiometry, pharmacokinetic characterization, safety assessment, biomarker development, and demonstration of reproducible effectiveness in human-relevant and large-animal models before evaluation in clinical trials.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149357494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Atorvastatin inhibits PASMC proliferation in pulmonary hypertension via the TLR4/NF-κB/NLRP3/IL-1β pathway.","authors":"Zhidian Cai, Zhihai Chen, Guili Lian, Yuxuan Zhang, Li Luo, Bangbang Huang","doi":"10.1097/FJC.0000000000001899","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001899","url":null,"abstract":"<p><p>Pulmonary hypertension (PH) is a progressive disorder leading to right heart failure. This study explored how atorvastatin (ATO) alleviates PH using a multidisciplinary approach. Network pharmacology, molecular docking, and dynamics analysis were employed to identify ATO targets. A PH rat model was established via monocrotaline (40 mg/kg) subcutaneous injection, and animals were divided into CT, PH, and ATO (10 mg/kg/day) groups. Hemodynamics, histopathology, and immunofluorescence were evaluated. In vitro, pulmonary arterial smooth muscle cells (PASMCs) were exposed to PDGF-BB (20 ng/ml) with or without ATO (10-8 M). Cell proliferation was measured by CCK-8 and PCNA expression, and key proteins in the TLR4/NF-κB/NLRP3/IL-1β pathway were analyzed via western blot. siRNA-NLRP3 was used to verify NLRP3's role in PASMCs proliferation. Network pharmacology identified 277 common targets, with KEGG analysis linking ATO to the NF-κB signaling pathway. Docking showed strong binding affinity between ATO and TLR4 (-6.3 kCal/mol) through non-covalent interactions with ASN464 and PHE487. In vivo, ATO reduced right ventricular systolic pressure, right ventricular hypertrophy and pulmonary artery thickening. Immunofluorescence confirmed NLRP3 co-localization with α-SMA+ PASMCs. ATO downregulated TLR4/NF-κB/NLRP3/IL-1β protein expression in PH rats' lungs and PASMCs, and suppressed PDGF-BB-induced PASMCs proliferation via the pathway inhibition. Direct knockdown of NLRP3 reduced both PDGF-BB-induced and non-PDGF-BB-induced proliferation of PASMCs, and ATO primarily inhibited PASMCs proliferation through NLRP3. These findings demonstrate that ATO directly targets TLR4 to inhibit NF-κB/NLRP3/IL-1β signaling, thereby reducing PASMCs proliferation and suppressing PH progression.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149357493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effective Protection Against Alcohol-Related Cardiac Damage: Dapagliflozin.","authors":"Cumaali Demirtas, Şahhan Kılıç, Mert Babaoğlu, Süha Asal, Elif Gökçe Tenekeci, Hakan Beyaztaş, Eray Metin Guler, Salime Pelin Erguven, Kubra Sevgin","doi":"10.1097/FJC.0000000000001877","DOIUrl":"10.1097/FJC.0000000000001877","url":null,"abstract":"<p><strong>Abstract: </strong>Chronic alcohol consumption causes serious damage to the liver and cardiovascular system and leads to neoplastic lesions in various organs such as the esophagus, liver, and breast. In our study, we evaluated the protective effects of standard and high doses of dapagliflozin against alcohol-related cardiac damage by using its anti-inflammatory, antifibrotic, and anticardiac remodeling effects with biochemical and pathological parameters. Twenty male and 20 female Sprague-Dawley rats were used in the experiments. The animals were randomly divided into 5 groups, with 4 male rats and 4 female rats in each group. The experimental groups (ALCOHOL, ALCOHOL + DAP, and ALCOHOL+hDAP groups) were given 20% ethyl alcohol intraperitoneally (i.p.) once daily for 28 days. Dapagliflozin (DAP, ALCOHOL + DAP, and ALCOHOL+hDAP groups) and saline solution (CONT and ALCOHOL groups) were administered orally via gavage (o.g.). In the hearts of animals exposed to alcohol, cardiomyocyte hypertrophy, irregular myofiber arrangement, widespread or focal infiltration of inflammatory cells such as neutrophils and lymphocytes, and marked cytoplasmic vacuolization were observed. Treatment with high-dose dapagliflozin alleviated these structural changes. Alcohol caused significant proximal tubular damage. High-dose dapagliflozin resulted in a greater reduction in alcohol-induced renal damage. Although standard dose of dapagliflozin improved alcohol-induced impaired caspase-3, cytokeratin 18-M30, cytokeratin 18-M65, TAS, TOS, OSI, MDA, IL-1β, TNF-α, HsCRP, endothelin-1, IMA, total thiol, native thiol, and disulfide levels, high-dose dapagliflozin provided significant improvements ( P < 0.001). This study suggests that high-dose dapagliflozin (3 mg/kg) may have the potential to regulate mitochondrial function and thiol/disulfide balance in alcohol-related heart damage by inhibiting fibrosis, hypertrophy, apoptosis, inflammation, and oxidative stress through various mechanisms.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"412-422"},"PeriodicalIF":2.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michael S Kelly, Jelena Lewis, Dylan Zuch, Mikhayla R Rogowsky, Dave L Dixon
{"title":"Olezarsen and Plozasiran: Novel apoC-III Targeting Medications for the Treatment of Hypertriglyceridemia.","authors":"Michael S Kelly, Jelena Lewis, Dylan Zuch, Mikhayla R Rogowsky, Dave L Dixon","doi":"10.1097/FJC.0000000000001854","DOIUrl":"10.1097/FJC.0000000000001854","url":null,"abstract":"<p><strong>Abstract: </strong>Hypertriglyceridemia is a prevalent lipid disorder associated with residual atherosclerotic cardiovascular disease risk and increased risk of acute pancreatitis at triglyceride (TG) levels above 1000 mg/dL. Causes of hypertriglyceridemia are multifactorial and may be a result of secondary causes (Western diet, alcohol, medications, uncontrolled diseases/disorders), genetic disorders, or a combination of both. Two novel medications (olezarsen, plozasiran), which inhibit hepatic production of apoC-III mRNA and increase TG clearance, have recently been approved to reduce TG levels in adults with familial chylomicronemia syndrome. Both olezarsen and plozasiran have been evaluated in randomized, placebo-controlled, clinical trials in patients with varying degrees of hypertriglyceridemia. In this review, we report the lipid-lowering effects and safety of both olezarsen and plozasiran from clinical trials in patients with hypertriglyceridemia. Based on available data, both agents are associated with significant TG-lowering effects by reductions in apoC-III and favorable effects on other lipid parameters. Overall, both agents seem generally well tolerated, although monitoring of liver enzymes and glycemic control is warranted for both agents, and additional monitoring of platelet counts for olezarsen. Future clinical trials are needed to assess whether the TG-lowering effects of each agent are associated with reduced risk of pancreatitis and atherosclerotic cardiovascular disease events.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"337-351"},"PeriodicalIF":2.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Saad Ashraf, Shariq A Wani, Muhammad Burhan, Muhammad A Naveed, Fnu Anchal, Hamza Irfan, Bazil Azeem, Ahila Ali
{"title":"Safety and Efficacy of Lorundrostat in Uncontrolled Hypertension: A Systematic Review and Meta-analysis.","authors":"Saad Ashraf, Shariq A Wani, Muhammad Burhan, Muhammad A Naveed, Fnu Anchal, Hamza Irfan, Bazil Azeem, Ahila Ali","doi":"10.1097/FJC.0000000000001857","DOIUrl":"10.1097/FJC.0000000000001857","url":null,"abstract":"<p><strong>Abstract: </strong>Uncontrolled hypertension remains a major global health concern and a leading cause of cardiovascular morbidity and mortality. Aldosterone dysregulation plays a critical role in resistant hypertension, and lorundrostat, a novel aldosterone synthase inhibitor, offers a promising therapeutic approach by directly inhibiting aldosterone production. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of lorundrostat in adults with uncontrolled hypertension. Comprehensive searches of MEDLINE (PubMed), ScienceDirect, Google Scholar, and Cochrane databases were conducted up to July 2025 following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, with the protocol registered on PROSPERO (CRD420251091117). Three randomized controlled trials involving 1568 participants (1165 lorundrostat and 403 placebo) were included, all demonstrating low risk of bias. Pooled analysis revealed that lorundrostat significantly reduced systolic blood pressure (BP) (-8.50 mm Hg, 95% confidence interval: -11.63 to -5.36, P < 0.00001) and diastolic BP (-3.53 mm Hg, 95% confidence interval: -5.61 to -1.45, P = 0.0009) compared with placebo, with no heterogeneity observed. However, lorundrostat was associated with higher risks of hyperkalemia (RR = 5.84, P = 0.01), symptomatic hypotension (RR = 2.98, P = 0.03), serious adverse events (RR = 3.31, P = 0.03), and hyponatremia (RR = 2.03, P = 0.01), although there were no significant differences in moderate or severe adverse events or reduction in kidney function. Publication bias was noted for diastolic BP and selected safety outcomes. In conclusion, lorundrostat demonstrates clinically meaningful BP reduction in uncontrolled hypertension compared with placebo, but with an increased risk of electrolyte disturbances and hypotension. Cautious use and close monitoring are warranted, and larger, long-term trials are needed to further define its safety and therapeutic role.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"355-363"},"PeriodicalIF":2.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effect of Sacubitril/Valsartan Versus Angiotensin Receptor Blocker or Calcium Channel Blockers on Ambulatory Blood Pressure and Safety in Hypertensive Patients: A Meta-Analysis of Randomized Controlled Trials.","authors":"Xueyi Li, Lige Gao, Wenqing Guo, Jiadi Li","doi":"10.1097/FJC.0000000000001879","DOIUrl":"10.1097/FJC.0000000000001879","url":null,"abstract":"<p><strong>Abstract: </strong>Sacubitril/valsartan, the first angiotensin receptor neprilysin inhibitor, has antihypertensive and organ-protective effects. However, previous meta-analyses have mainly compared it with angiotensin receptor blockers (ARBs) and neglected other commonly used antihypertensive agents, while its effect on ambulatory blood pressure remains unclear. This meta-analysis aimed to evaluate the efficacy and safety of sacubitril/valsartan in patients with hypertension. We searched CNKI, Wanfang, VIP, PubMed, Embase, and the Cochrane Library from inception to June 2025 for randomized controlled trials comparing sacubitril/valsartan with ARBs or calcium channel blockers (CCBs). Fifteen studies involving 4824 hypertensive patients were included. Compared with ARBs or CCBs, sacubitril/valsartan significantly reduced 24-hour systolic variability (24hSBPV) and 24-hour diastolic blood pressure variability (24hDBPV), as well as 24-hour, daytime, and nighttime ambulatory blood pressure. It also improved the dipper blood pressure proportion and blood pressure control rate. Subgroup analysis showed that both 200 and 400 mg/d dosages achieved superior antihypertensive efficacy. Regarding safety, sacubitril/valsartan had a similar adverse event profile to CCBs. Compared with ARBs, sacubitril/valsartan at 200 mg/d was associated with a lower incidence of serious adverse events, and the overall rate of liver function abnormalities was also reduced. Sensitivity analyses confirmed robust results with no significant publication bias. In conclusion, sacubitril/valsartan effectively improves multiple ambulatory blood pressure parameters with a favorable safety profile, supporting its rational use in hypertensive patients.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"367-395"},"PeriodicalIF":2.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149001852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Attilio Lauretti, Luigi Spadafora, Marco Bernardi, Antonio Di Matteo, Francesco Versaci
{"title":"ApoC-III Inhibition in Hypertriglyceridemia: From Triglyceride Lowering to Clinical Risk Modification.","authors":"Attilio Lauretti, Luigi Spadafora, Marco Bernardi, Antonio Di Matteo, Francesco Versaci","doi":"10.1097/FJC.0000000000001869","DOIUrl":"10.1097/FJC.0000000000001869","url":null,"abstract":"","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"352-354"},"PeriodicalIF":2.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148689152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Triple Antithrombotic Therapy for the Prevention of Left Ventricular Thrombus Following Anterior ST-Elevation Myocardial Infarction: A Systematic Review and Meta-Analysis.","authors":"Anastasios Apostolos, Vasileios Panoulas","doi":"10.1097/FJC.0000000000001872","DOIUrl":"10.1097/FJC.0000000000001872","url":null,"abstract":"<p><strong>Abstract: </strong>Left ventricular thrombus (LVT) is a serious complication of anterior ST-elevation myocardial infarction (STEMI). Despite guideline endorsement of prophylactic anticoagulation in selected high-risk patients, the supporting evidence remains of low certainty. The aim of our systematic review and meta-analysis was to evaluate the efficacy and safety of triple antithrombotic treatment (TAT) versus dual antiplatelet treatment (DAPT) alone for LVT prevention in patients with anterior STEMI treated with primary percutaneous coronary intervention (pPCI). Three electronic databases (EMBASE, MEDLINE, Cochrane Library) were systematically searched from inception to February 2026, following PRISMA 2020 guidelines. Eligible studies enrolled adult patients with anterior STEMI revascularized by pPCI, compared prophylactic TAT with DAPT alone, and reported LVT outcomes. Data were pooled as risk ratios (RRs) with 95% confidence intervals (CIs) using random-effects models. The primary outcome was LVT formation; secondary outcomes were major bleeding and systemic embolism. Six studies including 2021 patients were analyzed. Pooled analysis demonstrated no statistically significant reduction in LVT formation with TAT (RR: 0.54, 95% CI: 0.21-1.40; P = 0.21; I 2 = 61%), whereas major bleeding risk was significantly increased (RR: 2.69, 95% CI: 1.40-5.19; P = 0.003; I 2 = 14%). A nonsignificant trend toward reduced systemic embolism was observed (RR: 0.44, 95% CI: 0.18-1.07; P = 0.07; I 2 = 0%). The addition of prophylactic anticoagulation to DAPT in patients with anterior STEMI treated with pPCI does not show a statistically significant reduction in LVT formation while significantly increasing major bleeding risk. These findings do not support routine prophylactic TAT in unselected patients with anterior STEMI.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"423-431"},"PeriodicalIF":2.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}